Close Menu

NEW YORK (GenomeWeb) – Twist Bioscience and Pandion Therapeutics plan to use Twist's antibody optimization platform to develop therapeutics for autoimmune and inflammatory disease, the companies said today.

The firms did not disclose financial details of the agreement.

Twist "has a highly differentiated capability to optimize antibodies for many attributes including affinity, expression, solubility, half-life, immunogenicity, druggability, and processability," Anthony Coyle, co-founder and CEO of Pandion, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

At the Lancet, more than two dozen public health researchers condemn the conspiracy theories that have emerged surrounding the source of the COVID-19 outbreak.

The Washington Post reports that Philip Leder, who helped uncover how DNA codes for proteins and studied the role of genes in cancer, has died.

Researchers from Trinity College Dublin and the University of Pittsburgh look into how often de novo genes arise and how important they may be.

In Nucleic Acids Research this week: pipeline for genotyping Alu retrotransposon mobile element insertions, previously undocumented non-coding RNAs, and more.